Literature DB >> 20060366

The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Ulf Klein1, Marie Lia, Marta Crespo, Rachael Siegel, Qiong Shen, Tongwei Mo, Alberto Ambesi-Impiombato, Andrea Califano, Anna Migliazza, Govind Bhagat, Riccardo Dalla-Favera.   

Abstract

Chronic lymphocytic leukemia (CLL) is a malignancy of B cells of unknown etiology. Deletions of the chromosomal region 13q14 are commonly associated with CLL, with monoclonal B cell lymphocytosis (MBL), which occasionally precedes CLL, and with aggressive lymphoma, suggesting that this region contains a tumor-suppressor gene. Here, we demonstrate that deletion in mice of the 13q14-minimal deleted region (MDR), which encodes the DLEU2/miR-15a/16-1 cluster, causes development of indolent B cell-autonomous, clonal lymphoproliferative disorders, recapitulating the spectrum of CLL-associated phenotypes observed in humans. miR-15a/16-1-deletion accelerates the proliferation of both human and mouse B cells by modulating the expression of genes controlling cell-cycle progression. These results define the role of 13q14 deletions in the pathogenesis of CLL. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20060366     DOI: 10.1016/j.ccr.2009.11.019

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  348 in total

Review 1.  MicroRNAs, wild-type and mutant p53: more questions than answers.

Authors:  Matthew Jones; Ashish Lal
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

Review 2.  Role of microRNAs in lymphoid biology and disease.

Authors:  Muller Fabbri; Carlo M Croce
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

Review 3.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

Review 4.  Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?

Authors:  Leopold Sellner; Sascha Dietrich; Peter Dreger; Hanno Glimm; Thorsten Zenz
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

5.  miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells.

Authors:  Shaun Willimott; Simon D Wagner
Journal:  J Biol Chem       Date:  2011-12-02       Impact factor: 5.157

Review 6.  Long non-coding RNAs and cancer: a new frontier of translational research?

Authors:  R Spizzo; M I Almeida; A Colombatti; G A Calin
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

7.  miR-16 induction after CDK4 knockdown is mediated by c-Myc suppression and inhibits cell growth as well as sensitizes nasopharyngeal carcinoma cells to chemotherapy.

Authors:  Qingping Jiang; Yajie Zhang; Mengyang Zhao; Qiulian Li; Ruichao Chen; Xiaobing Long; Weiyi Fang; Zhen Liu
Journal:  Tumour Biol       Date:  2015-09-17

8.  Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia.

Authors:  Thirunavukkarasu Velusamy; Nallasivam Palanisamy; Shanker Kalyana-Sundaram; Anagh Anant Sahasrabuddhe; Christopher A Maher; Daniel R Robinson; David W Bahler; Timothy T Cornell; Thomas E Wilson; Megan S Lim; Arul M Chinnaiyan; Kojo S J Elenitoba-Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

9.  Epigenetic silencing of miR-125b is required for normal B-cell development.

Authors:  Guideng Li; Alex Yick-Lun So; Reeshelle Sookram; Stephanie Wong; Jessica K Wang; Yong Ouyang; Peng He; Yapeng Su; Rafael Casellas; David Baltimore
Journal:  Blood       Date:  2018-03-19       Impact factor: 22.113

10.  A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.

Authors:  Tint Lwin; Xiaohong Zhao; Fengdong Cheng; Xinwei Zhang; Andy Huang; Bijal Shah; Yizhuo Zhang; Lynn C Moscinski; Yong Sung Choi; Alan P Kozikowski; James E Bradner; William S Dalton; Eduardo Sotomayor; Jianguo Tao
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.